Post-transplant Hepatitis C Clinical Trial
Official title:
An Expanded Access Phase 2 Study of Sofosbuvir With Ribavirin and With or Without Pegylated Interferon for 24 Weeks in Subjects Who Have Undergone Liver Transplantation and Who Have Aggressive, Recurrent Hepatitis C Infection
| NCT number | NCT01779518 |
| Other study ID # | GS-US-334-0139 |
| Secondary ID | |
| Status | Approved for marketing |
| Phase | N/A |
| First received | January 23, 2013 |
| Last updated | January 15, 2014 |
This is a single arm, open-label study which will be opened at specific clinical sites at the request of an investigator for the treatment of individual subjects for whom there are no other treatment options. Subjects will be treated for 24 weeks with sofosbuvir (400mg QD) with RBV; pegylated interferon may be added at the discretion of the investigator.
| Status | Approved for marketing |
| Enrollment | 0 |
| Est. completion date | |
| Est. primary completion date | |
| Accepts healthy volunteers | |
| Gender | Both |
| Age group | 18 Years and older |
| Eligibility |
Inclusion Criteria: - Age > or = 18 years - Previously undergone orthotopic liver transplant (OLT) at least 2 months prior to the planned start of dosing - Aggressive Hepatitis C infection (including fibrosing cholestatic hepatitis C) - Life expectancy of < 12 months if the HCV is left untreated Exclusion Criteria: - History of clinically significant drug allergy to nucleoside/nucleotide analogs - Participation in a clinical study with an investigational drug or biologic within 1 month prior to anticipated dose administration, unless information is available to determine that there is no safety or drug-drug interaction risk to the subject - Unable or unwilling to follow the contraception requirements |
N/A
| Country | Name | City | State |
|---|---|---|---|
| n/a | |||
| Lead Sponsor | Collaborator |
|---|---|
| Gilead Sciences |